The Neurotech Industry Investing and Partnering Conference 2009

San Francisco, CA
Monday, May 11, 2009

Preliminary Agenda
St. Regis San Francisco
Tuesday May 12, 2009

7:30  Breakfast & Registration

8:00 Welcome: The Global Neurotech Industry 2009

Zack Lynch
Executive Director, Neurotechnology Industry Organization
8:30 Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Ellen Baron
Partner, Oxford Bioscience Partners

Andrew Jay
Managing Partner, Siemens Venture Capital

Vincent Kim
Partner, Aberdare Ventures

Matthew Perry
Portfolio Manager, Biotechnology Value Fund

Moderator: Casey Lynch
Managing Director, NeuroInsights

9:30 Networking and Refreshment Break

10:00 Novel Platforms for Drug Discovery and Device Development

Companies present novel approaches for discovering or repurposing shelved drugs screening platforms or improved delivery.  New device platforms pave the way for new neurostimulation products.

Daniel Abrams
Acting CEO, CSO/CMO, Sierra Neuropharmaceuticals

Thomas King

President and CEO, Alexza Pharmaceuticals

Paul McGonigle

Vice President External Scientific Affairs, PsychoGenics

Will Rosellini

President and CEO, MicroTransponder

Session Chair: Jeff Calcagno
Principal, Scale Venture Partners

11:15 Navigating the Global Regulatory Process - Panel Discussion

Intelligent clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving the design and finding the fastest route to approval. Case studies will demonstrate lessons learned in Alzheimer's, depression, pain and more.

Mark Demitrack
Chief Medical Officer,

Suzan Onel
Partner, NIO FDA Policy Advisor, K&L Gates

Cynthia Rask
Biotech/FDA Consultant

Moderator: Joyce Cramer
President, Epilepsy Therapy Project



1:30 Neurodegenerative Disease: Alzheimer's and Parkinson's

As the population ages, the market for Alzheimer's and Parkinson's is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

Richard Hadden

President and CEO, Cytox

Sam Henderson
Executive Director, Research, Accera

Daryl Kipke
President and CEO, NeuroNexus Technologies

John Mordock
President and CEO, Neurologix

Session Chair: John Reher
Managing Director, Brain Trust Accelerator Fund

2:45 Neuroscience Research & Development Partnerships

What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?

Brian Edmonds
Global External Research and Development, Lilly Research Labs, Eli Lilly

Carol Greve-Philips

Vice President, Corporate Development, Genzyme Corporation

Dave Schulz
Senior Director, Worldwide Business Development, Pfizer

Todd Whitehurst
Vice President Emerging Indications, Boston Scientific

Moderator: Dan O'Connell
Managing Partner, NeuroVentures Capital


3:45  Networking and Refreshment Break

4:15 Neuroregeneration and Stem Cells

What is the state of innovative therapies to promote neuronal regeneration and neuroplasticity? What is a realistic time frame for stem cell product candidates to begin reaching the clinic?

Deborah Eppstein
President and CEO, Q Therapeutics

Andres Haegerstrand
Chief Scientific Officer, NeuroNova

Jonathan Kil
President and CEO, Sound Pharmaceuticals

Stephen Huhn
Vice President CNS Programs, StemCells, Inc.

Session Chair: Roger Quy
General Partner, Technology Partners

5:30 Networking Reception and Wine Tasting

Sponsored by International Mental Health Research Organization
and Staglin Family Vineyards


Wednesday May 13, 2009


7:30 Continental Breakfast & Registration

8:30 Partnering and Licensing in Neurotech Panel

Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering? Is there a new model for partnerships emerging? Is Big pharma looking to earlier stage product candidates for partnering and inlicensing? Can major medical device companies continue with their high rate of acquisitions?

Lothar Krinke
Vice President, Research and Business Development, Medtronic Neuromodulation

David Paterson
Vice President, Business Development, Impax Pharmaceuticals

Shafique Virani
Director, Global Business Development, Roche

Yael Weiss
Director, Licensing and External Research, Merck

Session Chair: Christine de los Reyes
Managing Director, BiotechPartnering Solutions

9:30 NeuroVaccines: The Use of Vaccines in Neurology and Psychiatry


Vaccines are now being developed for a variety of brain and nervous system disorders from addiction to obesity, Alzheimer's to multiple sclerosis.  Companies will present a variety of approaches to vaccine development and discuss the benefits and risks of these cutting edge programs.

Raafat Fahim
President and CEO, Nabi

Mark Schwartz
President and CEO, Bayhill Therapeutics

Daniel Chain
Chairman and CEO, Intellect Neurosciences

Session Chair: Frank Eeckman
NeuroInsights, Neurotechnology Industry Organization

10:30 Networking and Refreshment Break

11:00 Traumatic Injury: Stroke, Traumatic Brain Injury, and Spinal Cord Injury
New hope is emerging for treatments of major traumatic injuries to the central nervous system. While highly challenging areas, companies are leveraging innovative financing to address these unmet markets.

Martin Dieck
President and CEO, NFocus

Shawn Lunney
CEO, Neurolutions

Vincent Simmon
President and CEO, Xytis

Michael Singer
CEO, BrainScope

Session Chair: Teo Forcht Dagi
Partner, HLM Venture Partners 

12:15 Partnering Lunch sponsored by The Neurotechnology Industry Organization

1:30 Neuroscience Translation, Tech Transfer and Collaboration Opportunities
Government representatives present opportunites for outlicensing, collaborative research, and clinical testing. 

Jamie Driscoll
Chief of Research Services, National Institute of Mental Health, NIH

Jill Heemskerk
Acting Director, Office of Translational Research
National Institute of Neurological Disorders and Stroke, NIH

Joe Pancrazio
Program Director, Extramural Research Program, Repair and Plasticity Cluster
National Institute of Neurological
Disorders and Stroke, NIH

Session Chair: Melissa Maderia
Technology Transfer Specialist, NINDS, NIH

2:15 Novel Platforms in Neurodevice Development 
As the first generation of neurodevices matures, a new generation of devices is advancing through preclinical and clinical studies. Companies with novel platforms for responsive and noninvasive neuromodulation are highlighted.

Frank Fischer
President and CEO, Neuropace

Ben Matteo

President and CEO, Eos Neuroscience

Andrew Thompson
CEO, Proteus Biomedical

Jamie Tyler
President and CEO, SynSonix

Session Chair: Kevin Wasserstein
Managing Director, Versant Ventures

3:30 Next Generation Neuropsychiatry
Schizophrenia, anxiety, depression, and other neuropsychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices change the treatment landscape?

Joe Belanoff

CEO, Corcept Therapeutics

Sharon Letchworth

Master Scientist, Targacept

Dan Segal

President North America, Brain Resource Company

Neal Simon

President and CEO, Azevan

Session Chair: Manuel Lopez-Figueroa
Vice President, Bay City Capital
4:45 Conference Concludes


Contact Information